Company news
Nektar Therapeutics news in 2019
Nektar Therapeutics's news releases, calls and decks from 2019, newest first.
Nektar Therapeutics Strengthens Board of Directors with Appointment of Myriam J. Curet, M.D.
December 16, 2019
Nektar Therapeutics Announces Presentation of New Preclinical Data for its IL-15 Agonist, NKTR-255, at the American Society of Hematology (ASH) 2019 Annual Meeting
December 8, 2019
Nektar Appoints John Northcott as Chief Commercial Officer
December 2, 2019
Nektar to Webcast Presentation at Jefferies 2019 London Healthcare Conference
November 12, 2019
Nektar Therapeutics Presents Data from First-in-Human Phase 1a Study on Novel T Regulatory Cell Stimulator, NKTR-358 at 2019 Annual Meeting of the American College of Rheumatology
November 9, 2019
Nektar Therapeutics to Host Webcast Conference Call with Melanoma Specialist for Analysts & Investors During 2019 Society for Immunotherapy of Cancer 34th Annual Meeting
October 31, 2019
Nektar to Announce Financial Results for the Third Quarter 2019 on Wednesday, November 6, 2019, After Close of U.S.-Based Financial Markets
October 29, 2019
Nektar Therapeutics Announces Initiation of First-in-Human Phase 1 Clinical Study of NKTR-255, an IL-15 Agonist, in Adults with Relapsed or Refractory Non-Hodgkin Lymphoma or Multiple Myeloma
October 15, 2019
Nektar Therapeutics Announces Initiation of Two Clinical Studies of Novel T Regulatory Cell Stimulator NKTR-358 (LY3471851) in Patients with Psoriasis and Atopic Dermatitis
October 6, 2019
Nektar Announces Key Executive Promotions
September 30, 2019
Nektar Therapeutics Announces Abstract Accepted for Presentation at the 5th CRI-CIMT-EATI-AACR Cancer Immunotherapy Conference
September 22, 2019
Nektar Therapeutics Reports Financial Results for the Second Quarter of 2019
August 7, 2019
Nektar Therapeutics and Bristol-Myers Squibb Announce U.S. FDA Breakthrough Therapy Designation for Bempegaldesleukin (NKTR-214) in Combination with Opdivo® (nivolumab) for the Treatment of Patients with Untreated Advanced Melanoma
July 31, 2019
Nektar to Announce Financial Results for the Second Quarter 2019 on Thursday, August 8, 2019, After Close of U.S.-Based Financial Markets
July 29, 2019
First-in-Human Data Presented from Phase 1a Study of NKTR-358, a Novel T Regulatory Cell Stimulator, at Annual European Congress of Rheumatology
June 12, 2019
Nektar Therapeutics to Host Webcast Conference Call with Immunology Expert for Analysts & Investors During 2019 European Congress of Rheumatology (EULAR 2019)
June 10, 2019
Nektar Announces the Launch of Inheris Biopharma, Inc.
May 22, 2019
Nektar to Announce Financial Results for the First Quarter 2019 on Wednesday, May 8, 2019, After Close of U.S.-Based Financial Markets
April 30, 2019
Nektar Therapeutics Presents Preclinical Data on its Immuno-Oncology Pipeline Candidates at the American Association for Cancer Research (AACR) Annual Meeting 2019
April 1, 2019
Vaccibody AS and Nektar Therapeutics Present New Preclinical Data from their Immuno-Oncology Collaboration at the American Association for Cancer Research (AACR) Annual Meeting 2019
March 31, 2019
Decks in 2019
- Technical Presentation (2019)
Technical · 22 slides · 2019